Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Updated FDA MRD guidelines for hematological malignancies

Nicole Gormley • 13 Sep 2019
IMW 2019
General

Nicole Gormley, MD, FDA, Silver Spring, MD, discusses the updated measurable residual disease (MRD) guidlines being produced by the FDA at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Nicole Gormley

2:08
Accelerating drug approval with better metrics in myeloma
Nicole Gormley • 13 Sep 2019

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals